SITC 2021 | Current status and future perspectives in immunotherapy for glioblastoma

Olivia Rongze Lu, PhD, University of Texas at Austin and Dell Medical School, Austin, TX, gives us an update on the current immunotherapeutic landscape for glioblastoma and outlines promising ongoing clinical trials, highlighting challenges in the development of effective immunotherapies for glioblastoma. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.